

CGRP Injection

Prior Authorization Request

Your patient's benefit plan requires prior authorization for certain medications. In order to make appropriate medical necessity determinations, your patient's diagnosis and other clinical information is required. Please complete the information requested on the form below and fax this form along with supporting clinical documentation to Priority Partners, toll-free at 1-866-212-4756 to initiate the review process. If you have questions regarding the prior authorization please contact Priority Partners at 888-819-1043 Option 4.

Patient's Name:	Date:
Patient's ID:	Patient's Date of Birth:
Physician's Name:	
Specialty:	NPI#:
Physician Office Telephone:	Physician Office Fax:
<u>Referring</u> Provider Info: Same as Requesting Provider	
Name:	NPI#:
Fax:	Phone:
Rendering Provider Info: Same as Referring Provider	Same as Requesting Provider
<u>Rendering</u> Provider Info: Same as Referring Provider Name:	Same as Requesting Provider NPI#:

Required Demographic Information:

Patient Weight:	_kg	
Patient Height:	<u>_</u> cm	
Drug Information:		
Strength/Measure		$Units \square ml \square Gm \square mg \square ea \square Un$
Directions(sig)		Route of administration
Dosing frequency		

Send completed form to: Priority Partners Fax: 1-866-212-4756

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. JHHC SOC CGRP Injection - 03/2022.

Priority Partners • 7231 Parkway Drive Suite 100 • Hanover, MD 21076

Phone: 888-819-1043 • Fax: 1-866-212-4756 • www.jhhc.com

Site of Service Questions:

- A. What drug is being requested?
 □ Ajovy, *skip to Clinical Criteria Questions*□ Vyepti
- B. Indicate the site of service requested:
 On Campus Outpatient Hospital
 Home based setting, *skip to Criteria Questions*Ambulatory infusion site, *skip to Criteria Ouestions*
- C. Is the patient less than 18 years of age?
 □ Yes, *skip to Clinical Criteria Questions*□ No

Off Campus Outpatient Hospital
 Community office, *skip to Criteria Questions*

- D. Has the patient experienced an adverse event with the requested product that has not responded to conventional interventions (eg acetaminophen, steroids, diphenhydramine, fluids, other pre- medications or slowing of infusion rate) or a severe adverse event (anaphylaxis, anaphylactoid reactions, myocardial infarction, thromboembolism, or seizures) during or immediately after an infusion? *ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation.* □ Yes, *skip to Clinical Criteria Questions* □ No
- E. Is the patient medically unstable which may include respiratory, cardiovascular, or renal conditions that may limit the member's ability to tolerate a large volume or load or predispose the member to a severe adverse event that cannot be managed in an alternate setting without appropriate medical personnel and equipment? *ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation.*Yes, *skip to Clinical Criteria Questions*
 No
- F. Does the patient have severe venous access issues that require the use of special interventions only available in the outpatient hospital setting? *ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation*.
 □ Yes, *skip to Clinical Criteria Questions* □ No
- G. Does the patient have significant behavioral issues and/or physical or cognitive impairment that would impact the safety of the infusion therapy AND the patient does not have access to a caregiver? *ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation.*Yes, *skip to Clinical Criteria Questions*
- H. Has the patient's home been deemed not eligible or appropriate for home infusion services by a home infusion provider? *ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation.*□ Yes, *skip to Clinical Criteria Questions* □ No
- I. Does the patient have severe venous access issues that require the use of special interventions only available in the outpatient hospital setting?
 ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation. □ Yes □ No

<u>Clinical Criteria Questions:</u>

- 1. What is the ICD-10 code?
- 2. Is the requested drug being prescribed for the preventive treatment of migraine in an adult patient? \Box Yes \Box No
- 3. Will the requested drug be used concurrently with another CGRP receptor antagonist? \Box Yes \Box No
- 4. Has the patient received at least 3 months of treatment with the requested drug? \Box Yes \Box No If No, skip to #7
- 5. Has the patient had a reduction in migraine days per month from baseline? \Box Yes \Box No
- 6. Does the patient require more than the plan allowance of any of the following:a) 1 injection of 140mg or 2 injections of 70mg per month of Aimovig,

Send completed form to: Priority Partners Fax: 1-866-212-4756

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. JHHC SOC CGRP Injection - 03/2022.

Priority Partners • 7231 Parkway Drive Suite 100 • Hanover, MD 21076

Phone: 888-819-1043 • Fax: 1-866-212-4756 • www.jhhc.com

- b) 3 injections (225mg each) per 3 months of Ajovy,
- c) 1 injection (120mg) per month of Emgality,
- d) 3 single dose vials (100mg each) for intravenous infusion per 3 months of Vyepti?
- □ Yes □ No No further questions
- 7. Has the patient experienced an inadequate treatment response with an 8-week trial of any of the following: A) Antiepileptic drugs (AEDs) (e.g., divalproex sodium, topiramate, valproate sodium), B) Beta-adrenergic blocking agents (e.g., metoprolol, propranolol, timolol, atenolol, nadolol), C) Antidepressants (e.g., amitriptyline, venlafaxine)? *If Yes, skip to #9* □ Yes □ No
- 8. Has the patient experienced an intolerance to or does the patient have a contraindication that would prohibit an 8week trial of any of the following: A) Antiepileptic drugs (AEDs) (e.g., divalproex sodium, topiramate, valproate sodium), B) Beta-adrenergic blocking agents (e.g., metoprolol, propranolol, timolol, atenolol, nadolol), C) Antidepressants (e.g., amitriptyline, venlafaxine)? □ Yes □ No
- 9. Does the patient require more than the plan allowance of any of the following: A) 1 injection of 140mg or 2 injections of 70mg per month of Aimovig, B) 3 injections (225mg each) per 3 months of Ajovy, C) 3 single dose vials (100mg each) for intravenous infusion per 3 months of Vyepti? □ Yes □ No

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by Priority Partners.

X

Prescriber or Authorized Signature

Date (mm/dd/yy)

Send completed form to: Priority Partners Fax: 1-866-212-4756

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. JHHC SOC CGRP Injection - 03/2022.

Priority Partners • 7231 Parkway Drive Suite 100 • Hanover, MD 21076

Phone: 888-819-1043 • Fax: 1-866-212-4756 • www.jhhc.com